## **Respiratory Disease** in Romania



## Introduction

The IRC, a coalition of respiratory clinicians, patients and industry partners, aims to transform post-pandemic respiratory care and reduce mortality by a third globally by 2030 - in line with the UN Sustainable Development Goals.

The IRC is calling on governments and policy makers to establish funded national strate-


gies, which include prevention, new models of care, ambitious measurable targets, and accountable leadership to improve lung health by focusing on:

## Better...

- Prevention of respiratory diseases 1.
- Access to the right treatment at the right time 2.
- 3. Action on reducing inequalities
- 4. Prioritisation of research, data and insight to improve care

The Romanian Society of Pneumology (RSP) - Societatea Română de Pneumologie (SRP) is in the process of partnering with different patient organisations and other professional and scientific associations in order to ensure the prevention and control of respiratory diseases, environmental protection, and to provide public education. Activities have included general public education on the prevention or treatment of respiratory diseases, actions regarding air pollution, and development and the implementation of programs and actions designed to prevent and fight respiratory diseases.

The IRC welcomes the work on this initiative and is also committed to collaborating with all relevant stakeholders in promoting lung health across Romania by developing national strategies.



Interstitial lung disease 673.7 RON million





Pulmonary arterial COVID-19 hypertension 71.3 RON 244.2 RON million billion

80.7 thousand deaths from respiratory diseases

million healthy life years lost to respiratory diseases





people living with

respiratory diseases

This initiative is made possible with the contributions of the partner organisations who all support the IRC's goals: Expertise and time were provided by the European Respiratory Society, European Lung Foundation and Global Allergy and Airways Patient Platform; funding, expertise and time were contributed by AstraZeneca, Chiesi Group, GSK, Sanofi and Regeneron; additional funding was provided by Boehringer Ingelheim.

Data taken from IRC Lung Facts https://international-respiratory-coalition.org/lung-facts/diseases/